cases surge across the continent.
backing the emergency use of the drug developed by Merck in
collaboration with Ridgeback Biotherapeutics, although it has not yet
been authorized by national authorities.
In a statement, the drug regulator said the medicine called Lagevrio – also known as molnupiravir or MK 4482 – “can
be used to treat adults with Covid-19 who do not require supplemental
oxygen and who are at increased risk of developing severe Covid-19.”
said the treatment should be administered as soon as possible after
Covid-19 is diagnosed and within five days of the start of symptoms. The
medicine should be taken twice a day for a period of five days.
EMA listed the potential side effects of the capsules, including mild
or moderate diarrhea, nausea, dizziness and headache. The treatment is
not recommended for pregnant women.
The watchdog announced earlier
on Friday that it had begun reviewing Pfizer’s medicine Paxlovid for
Covid-19 with the same goal “to support national authorities” who may decide on its early use prior to marketing authorization in light of rising cases and deaths in Europe.
Friday, Austria announced it would enter a new nationwide lockdown from
Monday and make vaccination mandatory, while Germany’s health
authorities claimed the country had turned into “one big outbreak.”
Pfizer and Merck have requested approval for their coronavirus
medicines from the US Food and Drug Administration, but it is unclear
when it might be granted.